Why vaccines may be overrated for COVID-19.

A summary of authorized drugs for Covid-19, those in development, and those that have failed.

How capital distorts the availability of biotechnology companies.

A new study highlights that there are likely fewer candidates for Flexion's star osteoarthritis treatment and this could affect the stock price of Flexion considerably.

An examination of the culture and demographics of India in relation to its economic potential.

While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?

Investment implications of Trump's Russia and China policies.

One can be wrong and make money and be right and lose money. Here is how I made money on Biogen Inc.

Using TA to bet against Verisign.

These charts demonstrate that the bear market is here.

After ISRG announced it had a new surgical machine that had been approved by the FDA, its stock shot up into the 500s. So is ISRG a buy? Not according to Ketan Desai who explains in this brief article the simple reasons why he bought ISRG puts.

Anticipating the FDA rejection of Sarepta Therapeutics's drug application for eteplirsen, Ketan Desai explains how he made money with an options strategy.

Many articles have been written about Myriad Genetics (MYGN) – some bullish, some bearish. This is a bearish article, looking at the company from a different angle.